Trump admin Sec 301 probes name Switzerland; pharma/metals tariffs confirmed with Swiss exceptions [developing]
Key Questions
What US tariffs have been confirmed for Swiss pharmaceuticals?
The Trump administration has confirmed 100% tariffs on patented drugs and APIs under Section 232, but Swiss products face 10-15% rates via MFN status and deals. Major firms like Novartis, Roche, and Genentech are safe until 2029 or July 31 through price cuts and onshoring, while Entresto and smaller biotechs are at risk with a 0-20% phase-in.
What tariffs apply to Swiss metals and machinery?
Swiss metals face 50% tariffs on raw materials, 25% on parts, and a 15% cap until 2027. Swissmem and the metals industry have expressed worries about costs and supply chain disruptions from these new US tariff rules.
What USTR probes involve Switzerland?
USTR launched Section 301 probes on March 12-13 into excess capacity and forced labor in 16 partners, including Switzerland's pharma, machinery, and chemicals sectors, with an April 15 deadline. The 2026 National Trade Estimate report highlights trade surpluses and deficits shrinking due to gold and tariffs, but no specific lists or actions against Switzerland yet.
How are Swiss industries and government responding to the tariffs?
Interpharma, Swissmem, biotechs, and the Swiss government warn of increased costs, supply chain issues, uncertainty, patient harm, and R&D impacts. Economy Minister Parmelin is holding ongoing talks, with recent confirmations of phase-ins and exemptions similar to UK deals.
Are there any exemptions or safe periods for Swiss pharma exports?
Swiss pharma giants like Novartis, Roche, and Genentech benefit from exemptions until 2029 or July 31 via negotiated deals involving price cuts and onshoring. Tariffs phase in at 0-20%, with lower 10-15% rates applied instead of the full 100% on patented drugs and APIs.
USTR Mar 12–13 probes excess capacity/forced labor in 16 partners incl. Switzerland (pharma/machinery/chemicals); Apr 15 deadline. Official Apr 2 Sec 232 confirms 100% pharma tariffs on patented drugs/APIs but Swiss at 10-15% via MFN/deals (Novartis/Roche/Genentech safe till '29/July31 via price-cuts/onshoring, Entresto/smaller biotechs at risk; 0-20% phase-in); metals 50% raw/25% parts/15% cap till '27. Interpharma/Swissmem/biotechs/Swiss govt warn costs/supply chains/uncertainty/patient harm/R&D. Parmelin talks ongoing, NTE/'Dirty 15' show surplus/deficit shrink on gold/tariffs, no lists/actions. Recent confirms phase-in/exemptions, UK deals.